A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, and effective immunotherapies, particularly when combined with other cancer treatments. The work examines the evolution of therapeutic cancer vaccines, with a special focus on neoantigen-based vaccines—highly personalized vaccines designed using genetic mutations unique to a patient’s tumor.
This article was originally published on MedicalXpress.com
